Next Article in Journal
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
Next Article in Special Issue
Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma
Previous Article in Journal
In Vivo Cell Fusion between Mesenchymal Stroma/Stem-Like Cells and Breast Cancer Cells
Previous Article in Special Issue
Mining-Guided Machine Learning Analyses Revealed the Latest Trends in Neuro-Oncology
Open AccessReview

Virus-Based Immunotherapy of Glioblastoma

Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, 75185 Uppsala, Sweden
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(2), 186; https://doi.org/10.3390/cancers11020186
Received: 21 December 2018 / Revised: 1 February 2019 / Accepted: 2 February 2019 / Published: 5 February 2019
(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
Glioblastoma (GBM) is the most common type of primary brain tumor in adults. Despite recent advances in cancer therapy, including the breakthrough of immunotherapy, the prognosis of GBM patients remains dismal. One of the new promising ways to therapeutically tackle the immunosuppressive GBM microenvironment is the use of engineered viruses that kill tumor cells via direct oncolysis and via stimulation of antitumor immune responses. In this review, we focus on recently published results of phase I/II clinical trials with different oncolytic viruses and the new interesting findings in preclinical models. From syngeneic preclinical GBM models, it seems evident that oncolytic virus-mediated destruction of GBM tissue coupled with strong adjuvant effect, provided by the robust stimulation of innate antiviral immune responses and adaptive anti-tumor T cell responses, can be harnessed as potent immunotherapy against GBM. Although clinical testing of oncolytic viruses against GBM is at an early stage, the promising results from these trials give hope for the effective treatment of GBM in the near future. View Full-Text
Keywords: oncolytic virotherapy; cancer immunotherapy; glioblastoma oncolytic virotherapy; cancer immunotherapy; glioblastoma
Show Figures

Figure 1

MDPI and ACS Style

Martikainen, M.; Essand, M. Virus-Based Immunotherapy of Glioblastoma. Cancers 2019, 11, 186.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop